首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学分子标靶治疗学细胞疗法基因疗法

市场调查报告书

商品编码

1490926

分子细胞遗传学市场 - 按产品类型、技术、应用、最终用途 - 全球预测

Molecular Cytogenetics Market - By Product Type, Technology, Application, End-use - Global Forecast 2024 - 2032

出版日期: 2024年03月22日 | 出版商:

Global Market Insights Inc. | 英文 278 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于对精确检测遗传异常和染色体变异的先进诊断技术的需求不断增长，预计 2024 年至 2032 年间，分子细胞遗传学市场规模的复合年增长率将达到 10.1%。萤光原位杂交 (FISH) 和比较基因组杂交 (CGH) 等技术在识别与各种疾病（包括癌症和遗传性疾病）相关的遗传变异方面具有高灵敏度和特异性。全球遗传性疾病和癌症的日益普及进一步推动了对分子细胞遗传学技术的需求，以实现精确诊断、预后和治疗计划。根据世界卫生组织的数据，2022 年，约有 2,000 万新发癌症病例，导致 970 万人死亡。

分子细胞遗传学平台的持续创新，例如下一代定序（NGS）和基于微阵列的技术，正在增强他们以更高的分辨率和通量分析染色体异常和结构变异的能力。此外，分子细胞遗传学与聚合酶炼式反应（PCR）和基因表现分析等其他分子生物学技术的整合，可实现全面的基因组分析和疾病的分子表征，这将促进市场成长。

分子细胞遗传学产业分为产品类型、技术、应用、最终用途和地区。

根据产品类型，仪器仪表领域的市场价值预计将产生可观的收入，到 2032 年复合年增长率为 9.9%。仪器提供的准确性、灵敏度和通量有利于这种增长，从而能够有效、可靠地检测染色体异常和遗传变异。仪器技术的不断进步，例如自动化、小型化和多路復用功能，也有助于简化工作流程、减少週转时间并提高资料质量，从而增加了它们在实验室和研究设施中的吸引力。

在对精确检测和表征遗传异常的先进诊断解决方案的需求的支持下，遗传性疾病应用领域的分子细胞遗传学行业预计在 2024 年至 2032 年期间将实现 9.9% 的增长率。分子细胞遗传学领域正在进行的研究和技术进步正在进一步增强其识别新型遗传标记和阐明遗传疾病潜在机制的能力，从而促进该细分市场的成长。

亚太地区分子细胞遗传学产业预计 2024 年至 2032 年复合年增长率为 10.4%。亚太地区人口不断增长，遗传性疾病盛行率不断上升，导致对先进诊断技术的需求不断增长，以满足医疗保健需求。旨在提高医疗保健可近性和负担能力的积极主动的政府倡议，加上不断增加的研发投资，也将促进分子细胞遗传学技术在该地区的采用。

产业生态系统分析
产业影响力
- 成长动力
  - 遗传性疾病和癌症的盛行率不断上升
  - 分子细胞遗传学的技术进步
  - 个人化医疗的采用不断增加
  - 扩大在研究和临床诊断的应用
- 产业陷阱与挑战
  - 严格的监管场景
  - 分子细胞遗传学检测成本高
成长潜力分析
技术景观
监管环境
波特的分析
PESTEL分析

第 4 章：竞争格局

介绍
公司市占率分析
竞争定位矩阵
战略展望矩阵

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

主要趋势
仪器
试剂和试剂盒
- 测试套件
- 探头
- 萤光亲和试剂
- 其他试剂和试剂盒
耗材
软体与服务

第 6 章：市场估计与预测：按技术划分，2021 - 2032 年

主要趋势
比较基因组杂交（CGH）
- 基于晶片的比较基因组杂交 (aCGH)
- 标准比较基因组杂交 (sCGH)
萤光原位杂交（FISH）
免疫组织化学
核型分析
- 光谱
- 虚拟的
其他技术

第 7 章：市场估计与预测：按应用分类，2021 - 2032

主要趋势
遗传性疾病
肿瘤学
个人化医疗
其他应用

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

主要趋势
临床和研究实验室
学术研究机构
製药和生物技术公司
其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 10 章：公司简介

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
BioView Ltd.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Illumina, Inc.
MetaSystems
PerkinElmer, Inc.
Sysmex Corporation

简介目录

Product Code: 8693

Molecular cytogenetics market size is projected to record 10.1% CAGR between 2024 and 2032, driven by the increasing demand for advanced diagnostic techniques to accurately detect genetic abnormalities and chromosomal alterations. Techniques, such as fluorescence in situ hybridization (FISH) and comparative genomic hybridization (CGH) offer high sensitivity and specificity in identifying genetic variations associated with various diseases, including cancer and genetic disorders. The growing prevalence of genetic disorders and cancer worldwide is further fueling the demand for molecular cytogenetics technologies for precise diagnosis, prognosis, and treatment planning. As per WHO, in 2022, there were approximately 20 million new cancer cases, resulting in 9.7 million deaths.

Continuous innovation in molecular cytogenetics platforms, such as next-generation sequencing (NGS) and microarray-based techniques is enhancing their capabilities in analyzing chromosomal abnormalities and structural variations at a higher resolution and throughput. Moreover, the integration of molecular cytogenetics with other molecular biology techniques like polymerase chain reaction (PCR) and gene expression analysis to enables comprehensive genomic profiling and molecular characterization of diseases will add to the market growth.

The molecular cytogenetics industry is classified into product type, technology, application, end-use and region.

Based on product type, the market value from the instruments segment is poised to generate substantial revenue, depicting a 9.9% CAGR through2032. The growth is favored by the accuracy, sensitivity, and throughput provided by instruments in enabling efficient and reliable detection of chromosomal abnormalities and genetic variations. Growing advancements in instrument technology, such as automation, miniaturization, and multiplexing capabilities also help streamline workflows, reduce turnaround times, and improve data quality, adding to their appeal in laboratories and research facilities.

Molecular cytogenetics industry from the genetic disorders application segment is slated to witness 9.9% growth rate during 2024-2032, backed by the demand for advanced diagnostic solutions to accurately detect and characterize genetic abnormalities. The ongoing research and technological advancements in molecular cytogenetics are further enhancing its capabilities in identifying novel genetic markers and elucidating the underlying mechanisms of genetic diseases, contributing to the segment growth.

Asia Pacific molecular cytogenetics industry is expected to grow at a 10.4% CAGR over 2024-2032. The expanding population and increasing prevalence of genetic disorders in APAC is contributing to the rising demand for advanced diagnostic technologies to address healthcare needs. The proactive government initiatives aimed at enhancing healthcare accessibility and affordability, coupled with the growing investments in R&D will also foster the adoption of molecular cytogenetics technologies in the region.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of genetic disorders and cancer
  - 3.2.1.2 Technological advancements in molecular cytogenetics
  - 3.2.1.3 Rising adoption of personalized medicine
  - 3.2.1.4 Expanding applications in research and clinical diagnostics
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory scenario
  - 3.2.2.2 High cost of molecular cytogenetic tests
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Instruments
5.3 Reagents and kits
- 5.3.1 Testing kits
- 5.3.2 Probes
- 5.3.3 Fluorescent affinity reagents
- 5.3.4 Other reagents and kits
5.4 Consumables
5.5 Software & services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Comparative genomic hybridization (CGH)
- 6.2.1 Array-based comparative genomic hybridization (aCGH)
- 6.2.2 Standard comparative genomic hybridization (sCGH)
6.3 Fluorescence in-situ hybridization (FISH)
6.4 Immunohistochemistry
6.5 Karyotyping
- 6.5.1 Spectral
- 6.5.2 Virtual
6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Genetic disorders
7.3 Oncology
7.4 Personalized medicine
7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Clinical & research laboratories
8.3 Academic research institutes
8.4 Pharmaceutical & biotech companies
8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa